AnaptysBio (ANAB) & The Competition Head-To-Head Review

AnaptysBio (NASDAQ:ANAB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare AnaptysBio to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Insider and Institutional Ownership

47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares AnaptysBio and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AnaptysBio	$234.60 million	-$13.23 million	8.66
AnaptysBio Competitors	$702.34 million	$9.48 million	-18.76

AnaptysBio’s peers have higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AnaptysBio and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1	3	12	0	2.69
AnaptysBio Competitors	9874	15294	45655	1600	2.54

AnaptysBio presently has a consensus target price of $75.67, indicating a potential upside of 62.76%. As a group, “Biotechnology” companies have a potential upside of 126.28%. Given AnaptysBio’s peers higher possible upside, analysts plainly believe AnaptysBio has less favorable growth aspects than its peers.

Profitability

This table compares AnaptysBio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AnaptysBio	82.37%	112.00%	2.20%
AnaptysBio Competitors	-12,323.33%	-195.91%	-30.60%

Risk and Volatility

AnaptysBio has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, AnaptysBio’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Summary

AnaptysBio beats its peers on 8 of the 13 factors compared.

About AnaptysBio

AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals.